Bioequivalence Study of Pediatric Formulations to Treat HIV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01469520
Recruitment Status : Unknown
Verified November 2011 by Elim Pediatric Pharmaceuticals Inc..
Recruitment status was:  Active, not recruiting
First Posted : November 10, 2011
Last Update Posted : November 10, 2011
Information provided by (Responsible Party):
Elim Pediatric Pharmaceuticals Inc.

No Study Results Posted on for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : November 2011
  Estimated Study Completion Date : December 2011
1. WHO UNAIDS and UNESCO 2010. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector: Progress Report 2010. p1-150. Accessed May 14, 2011, at 2. Ellis JC, L'homme R, Ewings FM, Mulenga V, Bell F, Chileshe R, Molyneux E, Abernethy J, van Oosterhout JJG, Chintu C 2007. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia Antivir Ther (Lond ) 12:253-260. 3. Kashuba AD, Swanstrom RI 2010. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. Antivir Ther (Lond ) 15:83-90.